Taken collectively, these preclinical findings in mouse syngeneic models indicate the GITR targeting results in enhanced Teff function, and induces potent anti-tumor efficacy – dependent upon both agonistic GITR signaling and Treg modulation – as neither mechanism singly fully rescues anti-tumor T cell responses [34, 35, 40]. The gene discussed is TNFRSF18; the disease is neoplasm.